title: The management of early-stage and metastatic triple-negative breast cancer: a review.
abstract: Triple-negative breast cancer (TNBC), defined as lacking expression of the estrogen receptor, progesterone receptor, and HER2, comprises approximately 15% of incident breast cancers and is over-represented among those with metastatic disease. There are several biologically distinct subtypes within TNBC. Although the incidence of BRCA mutations across all subsets of breast cancer is low, BRCA mutations are more common among those with TNBC and may have therapeutic implications. The general principles guiding the use of chemotherapy and radiation therapy do not differ dramatically between early-stage TNBC and non-TNBC.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA. carey_anders@med.unc.edu
authors.forename: Carey K
authors.initials: CK
authors.lastname: Anders
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Zagar
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Carey
mesh_terms: D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D064726:Triple Negative Breast Neoplasms / Q000473:pathology* / Q000628:therapy*
keywords: BRCA mutation; Breast cancer; Chemotherapy; Radiation; Targeted agents; Triple negative
references.citation: Radiother Oncol. 2011 Aug;100(2):200-4
references.pmid: 21852010
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2615-23
references.pmid: 22665533
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1004-9
references.pmid: 17418973
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references.pmid: 17438091
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
references.pmid: 17671126
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1145-53
references.pmid: 20100965
references.citation: Clin Cancer Res. 2012 Oct 1;18(19):5290-303
references.pmid: 22872574
references.citation: Mol Oncol. 2011 Feb;5(1):5-23
references.pmid: 21147047
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references.pmid: 12829800
references.citation: Mod Pathol. 2006 Feb;19(2):264-71
references.pmid: 16341146
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1082-9
references.pmid: 21233401
references.citation: Cancer Res. 2008 May 1;68(9):3108-14
references.pmid: 18451135
references.citation: Nature. 2012 Oct 4;490(7418):61-70
references.pmid: 23000897
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5367-74
references.pmid: 15328174
references.citation: Ann Surg Oncol. 2011 Oct;18(11):3164-73
references.pmid: 21947595
references.citation: Lancet Oncol. 2011 Sep;12(9):852-61
references.pmid: 21862407
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5652-7
references.pmid: 17116942
references.citation: Breast Cancer Res. 2008;10(6):R101
references.pmid: 19055754
references.citation: J Clin Oncol. 2011 Jul 20;29(21):2852-8
references.pmid: 21670451
references.citation: J Clin Oncol. 2006 May 1;24(13):2019-27
references.pmid: 16606972
references.citation: N Engl J Med. 2012 Jan 26;366(4):299-309
references.pmid: 22276820
references.citation: J Clin Invest. 2012 Apr;122(4):1541-52
references.pmid: 22446188
references.citation: J Clin Oncol. 2008 May 10;26(14):2373-8
references.pmid: 18413639
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: J Clin Oncol. 2004 Dec 1;22(23):4691-9
references.pmid: 15570071
references.citation: Clin Cancer Res. 2012 Apr 15;18(8):2402-12
references.pmid: 22351696
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5700-6
references.pmid: 19884543
references.citation: Breast Cancer Res. 2012 May 21;14(3):R79
references.pmid: 22613095
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2784-95
references.pmid: 20404251
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references.pmid: 18250347
references.citation: Cancer. 2012 Oct 15;118(20):4944-52
references.pmid: 22392492
references.citation: Mol Cell Biol. 2003 Nov;23(21):7488-97
references.pmid: 14559997
references.citation: J Clin Invest. 2011 Jul;121(7):2750-67
references.pmid: 21633166
references.citation: Cell. 2012 Apr 13;149(2):307-21
references.pmid: 22500798